{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:58:52Z","timestamp":1790013532944,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Research & Clinical Practice"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.orcp.2017.07.002","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T21:45:13Z","timestamp":1502747113000},"page":"501-521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current and emerging pharmacotherapies for obesity in Australia"],"prefix":"10.1016","volume":"11","author":[{"given":"Samantha","family":"Hocking","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Dear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Cowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.orcp.2017.07.002_bib0005","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/heapro\/dar036","article-title":"Future predictions of body mass index and overweight prevalence in Australia, 2005-2025","volume":"27","author":"Haby","year":"2012","journal-title":"Health Promot Int"},{"key":"10.1016\/j.orcp.2017.07.002_bib0010","doi-asserted-by":"crossref","first-page":"e0118599","DOI":"10.1371\/journal.pone.0118599","article-title":"The relationship between body mass index and hospitalisation rates, days in hospital and costs: findings from a large prospective linked data study","volume":"10","author":"Korda","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.orcp.2017.07.002_bib0015","unstructured":"AMA. Recognition of Obesity as a Disease. Available from: http:\/\/www.npr.org\/documents\/2013\/jun\/ama-resolution-obesity.pdf. [Accessed 30 May 2017]."},{"key":"10.1016\/j.orcp.2017.07.002_bib0020","series-title":"Obesity: preventing and managing the global epidemic","author":"WHO","year":"1998"},{"key":"10.1016\/j.orcp.2017.07.002_bib0025","unstructured":"ANZOS. The Australian and New Zealand Obesity Society management algorithm. Available at: http:\/\/anzos.com\/assets\/Obesity-Management-Algorithm-18.10.2016.pdf. [Accessed 30 May 2017]."},{"key":"10.1016\/j.orcp.2017.07.002_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3810\/pgm.2009.11.2074","article-title":"The medical risks of obesity","volume":"121","author":"Pi-Sunyer","year":"2009","journal-title":"Postgrad Med"},{"key":"10.1016\/j.orcp.2017.07.002_bib0035","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","article-title":"Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents","volume":"388","author":"Global BMI Mortality Collaboration","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.orcp.2017.07.002_bib0040","unstructured":"Summary guide for the management of overweight and obesity in primary care. https:\/\/www.nhmrc.gov.au\/_files_nhmrc\/publications\/attachments\/n57b_obesity_guidelines_summary_guide_131219.pdf."},{"key":"10.1016\/j.orcp.2017.07.002_bib0045","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/sj.ijo.0803015","article-title":"Long-term weight loss after diet and exercise: a systematic review","volume":"29","author":"Curioni","year":"2005","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.orcp.2017.07.002_bib0050","first-page":"8616581","article-title":"Through thick and thin: identifying barriers to bariatric surgery, weight loss maintenance, and tailoring obesity treatment for the future","author":"Westerveld","year":"2016","journal-title":"Surg Res Pract"},{"key":"10.1016\/j.orcp.2017.07.002_bib0055","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.orcp.2017.07.002_bib0060","doi-asserted-by":"crossref","first-page":"179674","DOI":"10.1155\/2011\/179674","article-title":"Pharmacotherapies for obesity: past, current, and future therapies","volume":"2011","author":"Ioannides-Demos","year":"2011","journal-title":"J Obes"},{"key":"10.1016\/j.orcp.2017.07.002_bib0065","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.orcp.2017.07.002_bib0070","doi-asserted-by":"crossref","first-page":"E1399","DOI":"10.1152\/ajpendo.00565.2011","article-title":"Serotonin 5-H T2C receptor-mediated inhibition of the M-current in hypothalamic POMC neurons","volume":"302","author":"Roepke","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.orcp.2017.07.002_bib0075","series-title":"Genes, behavior, and the social environment: moving beyond the nature\/nurture debate","first-page":"236","article-title":"Social environmental and genetic influences on obesity and obesity promoting behaviors: fostering research integration","author":"Faith","year":"2006"},{"key":"10.1016\/j.orcp.2017.07.002_bib0080","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","author":"Sumithran","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.orcp.2017.07.002_bib0085","series-title":"2007 Draft Guidance for Industry: Developing Products for Weight Management","author":"FDA","year":"2012"},{"key":"10.1016\/j.orcp.2017.07.002_bib0090","series-title":"Guideline on clinical evaluation of medicinal products used in weight control","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.orcp.2017.07.002_bib0095","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2125.1993.tb04228.x","article-title":"Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake","volume":"36","author":"Hartmann","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.orcp.2017.07.002_bib0100","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/oby.2009.155","article-title":"Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical)","volume":"18","author":"Kopelman","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.orcp.2017.07.002_bib0105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.orcp.2017.07.002_bib0110","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/archinte.1984.00350180055008","article-title":"A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination","volume":"144","author":"Weintraub","year":"1984","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.orcp.2017.07.002_bib0115","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.orcp.2017.07.002_bib0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized controlled trial of 30. mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.orcp.2017.07.002_bib0125","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 Diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.orcp.2017.07.002_bib0130","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.orcp.2017.07.002_bib0135","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study","volume":"20","author":"O\u2019Neil","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.orcp.2017.07.002_bib0140","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.orcp.2017.07.002_bib0145","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.orcp.2017.07.002_bib0150","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.orcp.2017.07.002_bib0155","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.orcp.2017.07.002_bib0160","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.orcp.2017.07.002_bib0165","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.orcp.2017.07.002_bib0170","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.orcp.2017.07.002_bib0175","unstructured":"Orlistat (Australian PI). Available at: http:\/\/www.guildlink.com.au\/gc\/ws\/ro\/pi.cfm?product=ropxencp11214. [Accessed 5 May 2017]."},{"key":"10.1016\/j.orcp.2017.07.002_bib0180","unstructured":"Phentermine (Australian PI). Available at: http:\/\/www.guildlink.com.au\/gc\/ws\/ia\/pi.cfm?product=iapdurom11113. [Accessed 5 May 2017]."},{"key":"10.1016\/j.orcp.2017.07.002_bib0185","series-title":"Saxenda (Australian PI)","author":"Novo Nordisk Pharmaceuticals Pty Limited","year":"2015"},{"key":"10.1016\/j.orcp.2017.07.002_bib0190","unstructured":"Lorcaserin (US PI). Available at: https:\/\/www.belviq.com\/-\/media\/Files\/BelviqConsolidation\/PDF\/Belviq_Prescribing_information-pdf.pdf?la=en. [Accessed 5 May 2017]."},{"key":"10.1016\/j.orcp.2017.07.002_bib0195","unstructured":"Naltrexone\/bupropion ER tablets (US PI). Available at: http:\/\/general.takedapharm.com\/content\/file.aspx?filetypecode=CONTRAVEPI&cacheRandomizer=3a174fd9-eb76-419c-abf5-c8d2582d7280. [Accessed 5 May 2017]."},{"key":"10.1016\/j.orcp.2017.07.002_bib0200","unstructured":"Phentermine\/topiramate ER (US PI). Available at: https:\/\/qsymia.com\/pdf\/prescribing-information.pdf. [Accessed 5 May 2017]."},{"key":"10.1016\/j.orcp.2017.07.002_bib0205","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.orcp.2017.07.002_bib0210","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can","year":"2014","journal-title":"Int J Obes (Lond)"},{"issue":"1 Suppl. 1","key":"10.1016\/j.orcp.2017.07.002_bib0215","first-page":"S85","article-title":"Liraglutide 3.0mg reduces severity of obstructive sleep apnoea and body weight in obese individuals with moderate or severe disease: SCALE Sleep Apnoea trial [abstract no. 184]","volume":"57","author":"Blackman","year":"2014","journal-title":"Diabetologia"},{"issue":"10077","key":"10.1016\/j.orcp.2017.07.002_bib0220","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.orcp.2017.07.002_bib0225","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1161\/CIRCULATIONAHA.113.006985","article-title":"Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease","volume":"129","author":"Smilowitz","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.orcp.2017.07.002_bib0230","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.orcp.2017.07.002_bib0235","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic safety of incretin-based drugs \u2014 FDA and EMA assessment","volume":"370","author":"Egan","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.orcp.2017.07.002_bib0240","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2337\/dc16-2684","article-title":"Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight\/obesity and normoglycemia, prediabetes, or type 2 Diabetes: secondary analyses of pooled data from the SCALE Clinical Development Program","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.orcp.2017.07.002_bib0245","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1172\/JCI70678","article-title":"Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype\u2013targeted drugs","volume":"123","author":"Meltzer","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.orcp.2017.07.002_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2014.04.004","article-title":"Naltrexone\/bupropion for obesity: an investigational combination pharmacotherapy for weight loss","volume":"84C","author":"Billes","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.orcp.2017.07.002_bib0255","first-page":"35","article-title":"Management of obesity and cardiometabolic risk \u2014 role of phentermine\/extended release topiramate","volume":"7","author":"Sweeting","year":"2014","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.orcp.2017.07.002_bib0260","unstructured":"EMA. Refusal of the marketing authorisation for Qsiva (phentermine\/topiramate). Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002350\/WC500139215.pdf. [Accessed 30 May 2017]."},{"key":"10.1016\/j.orcp.2017.07.002_bib0265","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1517\/14740338.2015.995088","article-title":"Why are anti-obesity drugs stigmatized?","volume":"14","author":"Halpern","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.orcp.2017.07.002_bib0270","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.orcp.2017.07.002_bib0275","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1001\/jama.2016.7602","article-title":"Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis","volume":"315","author":"Khera","year":"2016","journal-title":"JAMA"}],"container-title":["Obesity Research & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871403X17300650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871403X17300650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T07:44:35Z","timestamp":1658043875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871403X17300650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1871403X17300650"],"URL":"https:\/\/doi.org\/10.1016\/j.orcp.2017.07.002","relation":{},"ISSN":["1871-403X"],"issn-type":[{"value":"1871-403X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and emerging pharmacotherapies for obesity in Australia","name":"articletitle","label":"Article Title"},{"value":"Obesity Research & Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.orcp.2017.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}